Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study

INTRODUCTION: OnabotulinumtoxinA is approved in the USA for the prevention of headache in adults with chronic migraine, a debilitating neurologic disease characterized by headaches occurring on ≥ 15 days per month for > 3 months and including migraine features on ≥ 8 days per month. OBJECTIVE: Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Winner, Paul K., Blumenfeld, Andrew M., Eross, Eric J., Orejudos, Amelia C., Mirjah, Debbie L., Adams, Aubrey Manack, Brin, Mitchell F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647876/
https://www.ncbi.nlm.nih.gov/pubmed/31102144
http://dx.doi.org/10.1007/s40264-019-00824-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647876/
https://www.ncbi.nlm.nih.gov/pubmed/31102144
http://dx.doi.org/10.1007/s40264-019-00824-3

Ejemplares similares